Abstract
A single-center, retrospective review was performed between January 2009 and December 2019. A total of 26 patients with Marfan syndrome (MFS) underwent thoracic endovascular aorta repair (TEVAR) for Stanford type B aortic dissection (TBAD). The mean age was 38 years (range, 24-64 years). In-hospital mortality was 0%. The cumulative survival rate was 88% at 5 years and 83% at 10 years. Freedom from reintervention was 83% at 5 years and 50% at 10 years. Patients with a thrombosed false lumen (FL) along the length of the stent graft had a significantly higher cumulative survival rate and freedom from reintervention than patients with patent FL. TEVAR can be performed safely and effectively for TBAD in patients with MFS. Perioperative mortality and morbidity were low. Lifelong follow-up is mandatory to prevent aortic rupture. Patients with a patent FL were at high risk of late death.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
